The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Glossary Glossary
The Body Covers: The 12th International AIDS Conference
Can Antiretroviral Therapy Be Delivered in a Methadone Maintenance Setting?

July 2, 1998

Many practitioners hesitate to prescribe triple combination antiretroviral therapy to individuals with histories of illicit drug use and individuals in methadone maintenance programs because of the bias that these patients will not be able or willing to adhere to the pill taking schedule. The assumption is that poor adherence will lead to resistance and treatment failure. A group in Switzerland studied 51 patients in four methadone maintenance programs. All patients received ddI once daily and d4T and nelfinavir administered twice-a-day. Partially observed therapy was given, with one dose of each drug given together with methadone. Viral load and CD4+ count changes were measured together with a quality of life assessment.

Three patients were lost to follow-up, two refused to have blood taken for monitoring, and two stopped participation due to lack of adherence. However, the remaining patients faired well. 70% of patients said they took 90% of their medication, a fact confirmed by pill counts. Mean viral load reductions of approximately 2.0 log10 copies/mL were observed after 24 weeks of therapy, and CD4+ counts rose, on average, by over 200 cells/mm3. Further interest was provided by the quality of life measurements. Patients on antiretroviral therapy felt that their health and functioning were improved; they felt that they experienced less pain; and their energy was improved. Thus, antiretroviral therapy led to an improved sense of well being in these individuals.

This study provides encouragment that antiretroviral therapy can be provided in methadone maintenance settings with good results. More studies are needed to assess the challenges of providing therapy to this patient population, and longer periods of follow-up are needed to see if the favorable experience of this group can be continued over time.


Abstract: Nelfinavir, didanosine & stavudine in HIV-infected drug users enrolled in opiate substitution programs at four outpatient clinics -- The Zurich Prometheus study (Poster 42281)
Authored by: Markus Flepp, C. Nigg, F. Kuhn, M. Schaub, D. Meili, Bertino Somaini, P. Grob, and the Zurich Prometheus Study Team

See Also
Ask Our Expert, David Fawcett, Ph.D., L.C.S.W., About Substance Use and HIV
More on HIV Treatment for Substance Users

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.